Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 12/20 | 0.37 |
| ▸ | PARP6 | Q2NL67 | 5/20 | 0.37 |
| ▸ | PARP3 | Q9Y6F1 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 3/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31097522 | 0.89 | GPR119 (0.36) | BACE1USP30 | |
| SCHEMBL25321450 | 0.85 | PARP1 (0.39) | PARP1PARP2PARP6PARP3KCNH2 | |
| SCHEMBL31514813 | 0.83 | HDAC1 (0.45) | PARP1PARP2PARP6PARP3BACE1 | |
| SCHEMBL31514777 | 0.83 | HDAC1 (0.45) | PARP1PARP2PARP6PARP3BACE1 | |
| SCHEMBL31514778 | 0.81 | HDAC1 (0.45) | PARP1PARP2PARP6PARP3BACE1 | |
| SCHEMBL30869214 | 0.80 | SMARCA2 (0.47) | PARP1BACE1USP30 | |
| SCHEMBL25093504 | 0.80 | PARP1 (0.47) | PARP1USP30 | |
| SCHEMBL22912768 | 0.78 | BACE1 (0.53) | PARP1PARP2PARP6PARP3KCNH2 | |
| SCHEMBL29790202 | 0.78 | BACE1 (0.53) | PARP1PARP2PARP6PARP3KCNH2 | |
| SCHEMBL15765542 | 0.76 | SMN1; SMN2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171418-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4460497-A1 | PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-118574824-A | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2024-08-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171418-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | PARP1 1/4885PARP2 5/4885PARP6 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.